For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? Devel ...

It has been about a month since the last earnings report for Amedisys (AMED) . Shares have added about 5.5% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Amedisys due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Amedisys Q4 Earnings Miss Estimates, Margins Rise ...

Amedisys, Inc. (AMED) reported adjusted earnings per share (EPS) of $1.03 in the first quarter of 2024, which topped 3% from the year-ago quarter’s $1.00 per share. The bottom line also beat the Zacks Consensus Estimate by 1.9%. The quarter’s adjustments include certain merger-related expenses and other (income)/expenses, net. GAAP EPS in the first quarter was 59 cents compared to 23 cents in the same period last year. Net service revenues totaled $571.4 million, up 2.7% year over year. The top line surpass ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☒ EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☐ EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24260 AMEDISYS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 11-3131700 (State or other jurisdiction of (I ...

财务表现 - Amedisys（AMED）2024年第一季度营收为5.7141亿美元，同比增长2.7%[1] - 每股收益为1.03美元，较去年同期的1.00美元有所增长[1] - 公司的营收超出了Zacks Consensus Estimate的564.58亿美元，增幅为+1.21%；每股收益也超出了预期，增幅为+1.98%[2] 投资者关注点 - 投资者通常关注公司的营收和盈利变化，以及与华尔街预期的比较，以确定下一步的操作[3] 业务表现 - Amedisys在最近报告的季度中表现良好，特别是在家庭保健、高级护理和临终关怀方面的净服务收入方面[5][6][7] 股票表现 - 公司股票在过去一个月中的表现为-1.2%，而Zacks S&P 500综合指数为-3%[8]

Amedisys (AMED) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $1 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of 1.98%. A quarter ago, it was expected that this home health care and hospice services provider would post earnings of $1.04 per share when it actually produced earnings of $0.94, delivering a surprise of -9.62%. Over the l ...

BATON ROUGE, La., April 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2024. Three-Month Periods Ended March 31, 2024 and 2023 Net service revenue increased $15.0 million to $571.4 million compared to $556.4 million in 2023. Prior year included $15.0 million of net service revenue from our personal care business which was divested on March 31, 2023. Net income attributable to Amedisys, Inc. of $14.4 million, which is ...

净收入 - 2024年第一季度，Amedisys的净服务收入较2023年增加1500万美元，达到5.714亿美元[2] - 2024年第一季度，Amedisys的净收入为1440万美元，其中包括合并相关费用2070万美元（税后净额1980万美元），较2023年的2520万美元下降[2] - 2024年第一季度，AMEDISYS, INC.的Medicare部门净服务收入为2.158亿美元，较去年同期的2.154亿美元略有增长[16] - 2024年第一季度，AMEDISYS, INC.的Personal Care部门净服务收入为0美元，较去年同期的1.5亿美元下降[21] EBITDA - 2024年第一季度，Amedisys的调整后EBITDA为5990万美元，较2023年的5780万美元增长[3] - 2024年第一季度，AMEDISYS, INC.的调整后EBITDA为5.9859亿美元，较去年同期的5.7838亿美元有所增长[23] 现金流 - 在2024年第一季度，AMEDISYS, INC.的经营活动现金流为负6541千美元，较去年同期的25961千美元有所下降[13] - 2024年第一季度，AMEDISYS, INC.的投资活动现金流为负3068千美元，较去年同期的45896千美元有所下降[13] - 2024年第一季度，AMEDISYS, INC.的融资活动现金流为负8550千美元，较去年同期的56890千美元有所下降[13] 总体毛利 - 2024年第一季度，AMEDISYS, INC.的Home Health部门总体毛利为1.536亿美元，较去年同期的1.463亿美元有所增长[16] - 2024年第一季度，AMEDISYS, INC.的Hospice部门运营收入为4.69亿美元，较去年同期的4.35亿美元有所增长[19] - 2024年第一季度，AMEDISYS, INC.的High Acuity Care部门总体毛利为0.6亿美元，较去年同期的-0.8亿美元有所增长[22]

Zacks Premium - Zacks Premium提供多种方式帮助投资者充分利用股市并增强投资信心[1] - Zacks Premium包括Zacks Rank和Zacks Industry Rank的每日更新，Zacks 1 Rank List的完整访问权限，股票研究报告和高级股票筛选[2] - Zacks Style Scores是与Zacks Rank一起开发的互补指标，根据价值、增长和动量特征对股票进行评级，帮助投资者选择未来30天内市场表现最佳的股票[3]

A month has gone by since the last earnings report for Amedisys (AMED) . Shares have lost about 2.5% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Amedisys due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Amedisys Q4 Earnings Miss Estimates, Margins Rise Amedisy ...